Stay updated on Surufatinib & Toripalimab in Advanced Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Surufatinib & Toripalimab in Advanced Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib & Toripalimab in Advanced Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:26:16.000Z thumbnail image
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    8 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the objective response rate (ORR) of Surufatinib single agent in patients with advanced neuroendocrine carcinoma (NEC) or Surufatinib combined with Toripalimab in patients with advanced solid tumors in a phase II clinical study.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:49.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health conditions, and prior treatments. This change provides more comprehensive information about who can participate in the study.
    Difference
    48%
    Check dated 2024-05-22T21:16:50.000Z thumbnail image
  8. Check
    45 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:28:04.000Z thumbnail image

Stay in the know with updates to Surufatinib & Toripalimab in Advanced Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib & Toripalimab in Advanced Solid Tumors Clinical Trial page.